The National Health Service (NHS) is set to commence the world's most extensive trial of artificial intelligence (AI) in breast cancer screening, involving approximately 700,000 mammograms across England.

The initiative aims to evaluate AI's effectiveness in detecting breast cancer by comparing its performance to that of human radiologists.

If successful, the integration of AI could streamline the diagnostic process, potentially reducing the need for dual radiologist reviews and expediting patient diagnoses.

This trial is funded by the National Institute for Health and Care Research with an £11 million investment.

It builds upon prior research, including a 2023 Swedish study that indicated AI could safely reduce radiologists' workload by about 50% without increasing false positive rates.

The trial will be conducted at 30 breast cancer screening centers, where five distinct AI systems will analyze around 462,000 mammograms.

The remaining 238,000 scans will undergo traditional evaluation by two radiologists, allowing for a comprehensive comparison between AI-assisted and standard diagnostic methods.

Health Secretary Wes Streeting has announced plans for a new national cancer strategy, emphasizing the role of innovative technologies like AI in enhancing early detection and treatment outcomes.

While the trial holds promise for improving diagnostic efficiency, experts highlight the importance of ensuring AI algorithms are effective across diverse populations.

The trial's results are anticipated in the coming years, potentially informing future NHS screening protocols.